Fosamax for Glucocorticoid-Induced Osteoporosis

What Is Glucocorticoid-Induced Osteoporosis?

Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and the leading iatrogenic cause of the disease. Bone loss begins within the first three months of glucocorticoid therapy and accelerates rapidly during the first year, with fracture risk rising before measurable BMD changes appear on DXA.

Why Glucocorticoids Damage Bone

Glucocorticoids suppress osteoblast function and accelerate osteocyte apoptosis while simultaneously increasing osteoclast lifespan [3]. They also reduce intestinal calcium absorption and increase renal calcium excretion, creating a net negative calcium balance. The result is a dual hit: less new bone formation and faster existing bone resorption.

How Common Is GIOP?

Roughly 1% to 3% of the general population uses long-term oral glucocorticoids [4]. Among patients taking prednisone at doses of 5 mg/day or higher for 3 months or longer, vertebral fracture incidence reaches 30% to 50% over the treatment course [3]. That rate makes pharmacologic bone protection a clinical priority, not an afterthought.

The Fracture Risk Gap

Standard FRAX calculators underestimate fracture risk in glucocorticoid users because they do not fully account for the dose-dependent and duration-dependent effects of steroids on bone quality [2]. The 2022 ACR guidelines address this by recommending glucocorticoid-adjusted fracture risk assessment for any adult expected to receive prednisone-equivalent doses of 2.5 mg/day or more for 3 months or longer.

Alendronate's FDA-Approved Indications vs. Off-Label GIOP Use

The FDA approved alendronate (Fosamax) in 1995 for the treatment and prevention of postmenopausal osteoporosis. Subsequent approvals added male osteoporosis (2000) and Paget disease of bone. GIOP is conspicuously absent from the label.

Why There Is No FDA Approval for GIOP

Merck never pursued a supplemental new drug application (sNDA) for GIOP. Risedronate (Actonel) secured that indication in 2000, and the commercial incentive to run a separate GIOP registration program for alendronate diminished once risedronate filled the gap. The lack of an FDA indication does not reflect negative efficacy data. It reflects a business decision.

What "Off-Label" Means Clinically

Off-label prescribing is legal and common in the United States. An estimated 20% of all prescriptions are written for off-label indications [5]. For alendronate in GIOP, the off-label status means that insurers may require prior authorization, and clinicians should document the clinical rationale in the patient record. The evidence base, as detailed below, is strong enough to earn a conditional recommendation from the ACR.

Clinical Trial Evidence for Alendronate in GIOP

Two key randomized controlled trials evaluated alendronate specifically in patients receiving chronic glucocorticoids. Both were published in the late 1990s and remain the foundation of the evidence base.

The Saag 1998 Trial

Saag et al. (1998) randomized 477 men and women receiving at least 7.5 mg/day of prednisone or equivalent to alendronate 5 mg/day, alendronate 10 mg/day, or placebo for 48 weeks [1]. Lumbar spine BMD increased by 2.1% (5 mg) and 2.9% (10 mg) compared with 0.7% in the placebo group (P<0.001 for both). Femoral neck BMD also improved significantly in the 10 mg group. Vertebral fracture incidence was lower in the pooled alendronate groups (2.3%) than placebo (3.7%), though the study was not powered for fracture endpoints.

The Adachi 2001 Extension

Adachi et al. (2001) published a 2-year extension of the original cohort, confirming sustained BMD gains at the lumbar spine and femoral neck with continued alendronate use [6]. The 10 mg daily dose produced a cumulative lumbar spine BMD increase of approximately 3.9% over 2 years. No new safety signals emerged during the extension period.

Evidence Quality Assessment

By GRADE criteria, the evidence for alendronate in GIOP is rated moderate. The RCTs were well-designed and adequately powered for BMD outcomes, but they were underpowered for fracture reduction. No large fracture-endpoint trial exists for alendronate in GIOP specifically, which is the primary gap in the evidence base.

What the 2022 ACR Guidelines Recommend

The 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis conditionally recommends oral bisphosphonates (alendronate, risedronate, or zoledronic acid) for adults at moderate-to-high fracture risk who are initiating or continuing glucocorticoids at prednisone-equivalent doses of 2.5 mg/day or more for 3 months or longer [2].

ACR Risk Stratification

The ACR stratifies GIOP patients into three tiers:

• Low risk: FRAX 10-year major osteoporotic fracture probability <10% (glucocorticoid-adjusted). Optimize calcium, vitamin D, and lifestyle modifications first.
• Moderate risk: FRAX 10% to 19%. Oral bisphosphonates are conditionally recommended.
• High risk: FRAX 20% or greater, prior osteoporotic fracture, or hip/spine T-score of -2.5 or below. Oral bisphosphonates, IV zoledronic acid, denosumab, or teriparatide are all conditionally recommended, with teriparatide or denosumab preferred over oral bisphosphonates.

Where Alendronate Fits

The guideline does not single out alendronate by name as a first choice. It groups oral bisphosphonates together. In practice, clinicians choose between alendronate and risedronate based on cost, availability, and whether the patient's insurer requires an on-label agent. For high-risk patients, the ACR gives a conditional recommendation favoring teriparatide or denosumab over oral bisphosphonates, citing stronger fracture-reduction data in those populations.

The Endocrine Society's 2023 clinical practice guideline on osteoporosis pharmacotherapy echoes this positioning, recommending bisphosphonates as initial therapy for most patients with osteoporosis and noting that the choice among bisphosphonates depends on clinical context and patient preference [7].

Alendronate vs. Risedronate: The On-Label Comparison

Risedronate (Actonel) holds an explicit FDA approval for GIOP prevention and treatment. This gives it a regulatory advantage over alendronate, but the clinical differences are modest.

Efficacy Comparison

Reid et al. (2000) showed that risedronate 5 mg/day increased lumbar spine BMD by 2.9% vs. 1.0% for placebo over 12 months in glucocorticoid-treated patients, with a 70% reduction in vertebral fracture risk [8]. Alendronate 10 mg/day produced a comparable 2.9% lumbar spine BMD increase over 48 weeks in the Saag trial [1]. No head-to-head RCT has directly compared alendronate to risedronate in GIOP.

Cost and Access

Generic alendronate 70 mg weekly tablets cost $4 to $15 per month at most U.S. Pharmacies. Generic risedronate 35 mg weekly costs approximately $15 to $40 per month. When cost is the deciding factor, alendronate offers a meaningful advantage, particularly for uninsured patients or those with high-deductible plans.

Insurance Considerations

Because risedronate carries the FDA-approved GIOP indication, some insurance formularies list it as preferred for steroid-treated patients. If a plan denies alendronate coverage for GIOP, the prescribing clinician may need to submit a prior authorization with supporting literature or switch to risedronate.

Risks and Side Effects Specific to GIOP Patients

The adverse-effect profile of alendronate in GIOP patients mirrors its profile in postmenopausal osteoporosis, with a few glucocorticoid-specific considerations.

Gastrointestinal Risks

Esophageal irritation, dyspepsia, and abdominal pain are the most common complaints. Glucocorticoid users already face elevated GI risk from steroids themselves, and the combination with an oral bisphosphonate compounds this concern. Patients must follow strict dosing instructions: take alendronate on an empty stomach with 8 oz of plain water, remain upright for at least 30 minutes, and avoid food or other medications during that window [9].

Atypical Femoral Fractures

Prolonged bisphosphonate use (>5 years) is associated with atypical subtrochanteric or diaphyseal femoral fractures. The absolute risk is low, estimated at 3.2 to 50 cases per 100,000 person-years of bisphosphonate use depending on duration [10]. In GIOP patients, the benefit-risk calculus often favors continued treatment because the fracture risk from undertreated steroid-induced bone loss typically exceeds the atypical fracture risk from the bisphosphonate.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is rare with oral bisphosphonates, occurring at an estimated rate of 1 per 10,000 to 1 per 100,000 patient-years [10]. The risk is substantially higher with high-dose IV bisphosphonates used in oncology. Dental evaluation before starting long-term alendronate is a reasonable precaution, particularly in patients on concurrent immunosuppressive therapy.

Hypocalcemia

Glucocorticoids impair calcium absorption, and bisphosphonates can further lower serum calcium. All GIOP patients starting alendronate should receive concurrent calcium (1,000 to 1,200 mg/day) and vitamin D (at least 800 IU/day, with a target 25-hydroxyvitamin D level of 30 ng/mL or above) [2].

When to Choose a Different Agent

Alendronate is a reasonable option for moderate-risk GIOP, but several clinical scenarios call for a different drug.

Teriparatide for High-Risk Patients

The Saag et al. (2007) trial directly compared teriparatide 20 mcg/day to alendronate 10 mg/day in 428 glucocorticoid-treated patients over 18 months [11]. Teriparatide produced significantly greater lumbar spine BMD gains (7.2% vs. 3.4%) and fewer new vertebral fractures (0.6% vs. 6.1%, P=0.004). For patients with prior fractures, T-scores below -2.5, or FRAX scores of 20% or greater, teriparatide is the stronger choice.

Dr. Kenneth Saag, the lead investigator on both the 1998 alendronate GIOP trial and the 2007 teriparatide comparison, stated: "In patients at highest fracture risk from glucocorticoids, anabolic therapy with teriparatide provides fracture protection that antiresorptive agents alone cannot match" [11].

Denosumab

Denosumab (Prolia) 60 mg subcutaneously every 6 months received a conditional recommendation in the 2022 ACR guidelines for high-risk GIOP [2]. It avoids the GI tolerability issues of oral bisphosphonates and does not require renal dose adjustment. The tradeoff: stopping denosumab triggers rapid bone loss (rebound resorption), requiring a bisphosphonate "bridge" upon discontinuation.

Zoledronic Acid

IV zoledronic acid 5 mg once yearly is an option for patients who cannot tolerate oral bisphosphonates. Reid et al. (2009) demonstrated non-inferiority of zoledronic acid to risedronate for GIOP prevention, with superior lumbar spine BMD gains at 12 months [12].

Dosing and Monitoring for Off-Label GIOP Use

Clinicians prescribing alendronate off-label for GIOP typically use the same doses approved for postmenopausal osteoporosis. No GIOP-specific dose adjustment has been validated.

Standard Dosing

• Treatment dose: 70 mg once weekly or 10 mg once daily
• Prevention dose (sometimes used for lower-risk patients): 35 mg once weekly or 5 mg once daily

The 70 mg weekly formulation is preferred for adherence. Take it on the same day each week.

Baseline and Follow-Up Testing

Before starting therapy: DXA scan of the lumbar spine and hip, serum 25-hydroxyvitamin D, basic metabolic panel (calcium, creatinine), and dental evaluation if prolonged use is anticipated.

Repeat DXA at 1 to 2 years. If BMD is stable or improving and the patient remains on glucocorticoids, continue alendronate. If BMD declines despite treatment, consider switching to teriparatide or denosumab. The ACR recommends reassessing fracture risk every 1 to 3 years in patients on chronic glucocorticoids [2].

Duration of Therapy

There is no consensus on treatment duration for GIOP specifically. General osteoporosis guidelines suggest a bisphosphonate holiday after 5 years of oral therapy (or 3 years of IV zoledronic acid) in patients whose fracture risk has decreased [7]. In GIOP, however, bone loss resumes if glucocorticoids continue, so many clinicians extend bisphosphonate treatment beyond 5 years for patients on chronic steroids, with periodic reassessment.

The Cost-Effectiveness Argument

A 2019 systematic review of economic evaluations in GIOP found that oral bisphosphonates were the most cost-effective first-line pharmacologic intervention for moderate-risk patients, with incremental cost-effectiveness ratios well below standard willingness-to-pay thresholds [13]. Generic alendronate, at roughly $4 to $15 per month, represents one of the lowest per-month costs of any osteoporosis treatment.

For context, teriparatide (Forteo) costs approximately $3,500 per month without insurance, and denosumab (Prolia) runs roughly $1,600 per injection every 6 months. When fracture risk is moderate and cost is a barrier, generic alendronate becomes the pragmatic choice despite its off-label status.

The 2022 ACR guideline panel noted: "Cost and access considerations may reasonably influence the choice among conditionally recommended therapies, particularly when clinical efficacy differences are modest" [2].